| Year |
Citation |
Score |
| 2024 |
Kaczmarek R, Samelson-Jones BJ, Herzog RW. Immune tolerance induction by hepatic gene transfer: First-in-human evidence. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 38518767 DOI: 10.1016/j.ymthe.2024.03.016 |
0.333 |
|
| 2024 |
Rana J, Herzog RW, Muñoz-Melero M, Yamada K, Kumar SRP, Lam AK, Markusic DM, Duan D, Terhorst C, Byrne BJ, Corti M, Biswas M. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver. Molecular Therapy. Methods & Clinical Development. 32: 101216. PMID 38440160 DOI: 10.1016/j.omtm.2024.101216 |
0.491 |
|
| 2024 |
Zhang J, Frabutt DA, Chrzanowski M, Li N, Miller LM, Tian J, Mulcrone PL, Lam AK, Draper BE, Jarrold MF, Herzog RW, Xiao W. A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR. Molecular Therapy. Methods & Clinical Development. 32: 101206. PMID 38390555 DOI: 10.1016/j.omtm.2024.101206 |
0.318 |
|
| 2023 |
Kumar SRP, Biswas M, Cao D, Arisa S, Melero MM, Lam AK, Piñeros AR, Kapur R, Kaisho T, Kaufman RJ, Xiao W, Shayakhmetov DM, Terhorst C, de Jong YP, Herzog RW. TLR9-independent CD8 T Cell Responses in Hepatic AAV Gene Transfer Through IL-1R1-MyD88 Signaling. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 38053332 DOI: 10.1016/j.ymthe.2023.11.029 |
0.336 |
|
| 2023 |
Biswas M, So K, Bertolini TB, Krishnan P, Rana J, Muñoz-Melero M, Syed F, Kumar SRP, Gao H, Xuei X, Terhorst C, Daniell H, Cao S, Herzog RW. Distinct functions and transcriptional signatures in orally induced regulatory T cell populations. Frontiers in Immunology. 14: 1278184. PMID 37954612 DOI: 10.3389/fimmu.2023.1278184 |
0.327 |
|
| 2023 |
Chen Z, Herzog RW, Kaufman RJ. Cellular stress and coagulation factor production: when more isn't necessarily better. Journal of Thrombosis and Haemostasis : Jth. PMID 37839613 DOI: 10.1016/j.jtha.2023.10.005 |
0.339 |
|
| 2023 |
Butterfield JSS, Li X, Arisa S, Kwon KC, Daniell H, Herzog RW. Potential role for oral tolerance in gene therapy. Cellular Immunology. 104742. PMID 37423874 DOI: 10.1016/j.cellimm.2023.104742 |
0.451 |
|
| 2023 |
Valentino LA, Ozelo MC, Herzog RW, Key NS, Pishko AM, Ragni MV, Samelson-Jones BJ, Lillicrap D. A Review of the Rationale for Gene Therapy for Hemophilia A With Inhibitors: One-Shot Tolerance and Treatment? Journal of Thrombosis and Haemostasis : Jth. PMID 37225021 DOI: 10.1016/j.jtha.2023.05.011 |
0.363 |
|
| 2023 |
Kaczmarek R, Pineros AR, Patterson PE, Bertolini TB, Perrin GQ, Sherman A, Born J, Arisa S, Arvin MC, Kamocka MM, Martinez Irizarry MM, Dunn KW, Quinn SM, Morris JJ, Wilhelm AR, ... ... Herzog RW, et al. Factor VIII Trafficking to CD4+ T cells Shapes its Immunogenicity and Requires Several Types of Antigen Presenting Cells. Blood. PMID 37192286 DOI: 10.1182/blood.2022018937 |
0.346 |
|
| 2023 |
Kumar SRP, Duan D, Herzog R. Immune Responses to Muscle-Directed AAV Gene Transfer in Clinical Studies. Human Gene Therapy. PMID 37154743 DOI: 10.1089/hum.2023.056 |
0.404 |
|
| 2023 |
Bertolini TB, Herzog RW, Kumar SRP, Sherman A, Rana J, Kaczmarek R, Yamada K, Arisa S, Lillicrap D, Terhorst C, Daniell H, Biswas M. Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice. Cellular Immunology. 385: 104675. PMID 36746071 DOI: 10.1016/j.cellimm.2023.104675 |
0.352 |
|
| 2022 |
Hakim CH, Kumar SRP, Pérez-López D, Teixeira J, Herzog RW, Duan D. Assessment of the Gene Therapy Immune Response in the Canine Muscular Dystrophy Model. Methods in Molecular Biology (Clifton, N.J.). 2587: 353-375. PMID 36401038 DOI: 10.1007/978-1-0716-2772-3_18 |
0.415 |
|
| 2022 |
Butterfield JSS, Yamada K, Bertolini TB, Syed F, Kumar SRP, Li X, Arisa S, Piñeros AR, Tapia A, Rogers CA, Li N, Rana J, Biswas M, Terhorst C, Kaufman RJ, ... ... Herzog RW, et al. IL-15 Blockade and Rapamycin Rescue Multifactorial Loss of Factor VIII from AAV-Transduced Hepatocytes in Hemophilia A Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 35821634 DOI: 10.1016/j.ymthe.2022.07.005 |
0.399 |
|
| 2022 |
Arruda VR, Lillicrap D, Herzog RW. Immune Complications and their Management in Inherited and Acquired Bleeding Disorders. Blood. PMID 35793465 DOI: 10.1182/blood.2022016530 |
0.379 |
|
| 2021 |
Hakim CH, Kumar SRP, Pérez-López DO, Wasala NB, Zhang D, Yue Y, Teixeira J, Pan X, Zhang K, Million ED, Nelson CE, Metzger S, Han J, Louderman JA, Schmidt F, ... ... Herzog RW, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nature Communications. 12: 6769. PMID 34819506 DOI: 10.1038/s41467-021-26830-7 |
0.373 |
|
| 2021 |
Kumar SRP, Xie J, Hu S, Ko J, Huang Q, Brown HC, Srivastava A, Markusic DM, Doering CB, Spencer HT, Srivastava A, Gao G, Herzog RW. Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette. Molecular Therapy. Methods & Clinical Development. 23: 98-107. PMID 34631930 DOI: 10.1016/j.omtm.2021.08.001 |
0.405 |
|
| 2021 |
Bertolini TB, Shirley JL, Zolotukhin I, Li X, Kaisho T, Xiao W, Kumar SRP, Herzog RW. Effect of CpG Depletion of Vector Genome on CD8 T Cell Responses in AAV Gene Therapy. Frontiers in Immunology. 12: 672449. PMID 34135899 DOI: 10.3389/fimmu.2021.672449 |
0.451 |
|
| 2021 |
Srinivasan A, Herzog RW, Khan I, Sherman A, Bertolini T, Wynn T, Daniell H. Preclinical Development of Plant-based Oral Immune Modulatory Therapy for Hemophilia B. Plant Biotechnology Journal. PMID 33949086 DOI: 10.1111/pbi.13608 |
0.302 |
|
| 2020 |
Bertolini TB, Biswas M, Terhorst C, Daniell H, Herzog RW, Piñeros AR. Role of orally induced regulatory T cells in immunotherapy and tolerance. Cellular Immunology. 359: 104251. PMID 33248367 DOI: 10.1016/j.cellimm.2020.104251 |
0.302 |
|
| 2020 |
Biswas M, Marsic D, Li N, Zou C, Gonzalez-Aseguinolaza G, Zolotukhin I, Kumar SRP, Rana J, Butterfield JSS, Kondratov O, de Jong YP, Herzog RW, Zolotukhin S. Engineering and Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity. Molecular Therapy. Methods & Clinical Development. 19: 347-361. PMID 33145371 DOI: 10.1016/j.omtm.2020.09.019 |
0.314 |
|
| 2020 |
Brown HC, Doering CB, Herzog R, Ling C, Markusic DM, Spencer HT, Srivastava A, Srivastava A. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. Human Gene Therapy. PMID 32657150 DOI: 10.1089/Hum.2020.099 |
0.391 |
|
| 2020 |
Zou C, Vercauteren KOA, Michailidis E, Kabbani M, Zoluthkin I, Quirk C, Chiriboga L, Yazicioglu M, Anguela XM, Meuleman P, High KA, Herzog RW, de Jong YP. Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice. Molecular Therapy. Methods & Clinical Development. 18: 189-198. PMID 32637450 DOI: 10.1016/J.Omtm.2020.05.033 |
0.511 |
|
| 2020 |
Kumar SRP, Wang X, Avuthu N, Bertolini TB, Terhorst C, Guda C, Daniell H, Herzog RW. Role of Small Intestine and Gut Microbiome in Plant-Based Oral Tolerance for Hemophilia. Frontiers in Immunology. 11: 844. PMID 32508814 DOI: 10.3389/Fimmu.2020.00844 |
0.45 |
|
| 2020 |
Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31968213 DOI: 10.1016/j.ymthe.2020.01.001 |
0.395 |
|
| 2020 |
Herzog RW. Encouraging and Unsettling Findings in Long-Term Follow-up of AAV Gene Transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31951831 DOI: 10.1016/J.Ymthe.2020.01.007 |
0.335 |
|
| 2020 |
Michailidis E, Vercauteren K, Mancio-Silva L, Andrus L, Jahan C, Ricardo-Lax I, Zou C, Kabbani M, Park P, Quirk C, Pyrgaki C, Razooky B, Verhoye L, Zoluthkin I, Lu WY, ... ... Herzog RW, et al. Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America. PMID 31915293 DOI: 10.1073/Pnas.1919035117 |
0.357 |
|
| 2019 |
Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. A Molecular Revolution in the Treatment of Hemophilia. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31843450 DOI: 10.1016/J.Ymthe.2019.11.006 |
0.455 |
|
| 2019 |
Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE, Morel LM, Wallet MA, Terhorst C, Herzog RW. Type I IFN Sensing by cDCs and CD4 T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8 T Cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31780366 DOI: 10.1016/J.Ymthe.2019.11.011 |
0.491 |
|
| 2019 |
Daniell H, Kulis M, Herzog RW. Plant cell-made protein antigens for induction of Oral tolerance. Biotechnology Advances. PMID 31251968 DOI: 10.1016/J.Biotechadv.2019.06.012 |
0.317 |
|
| 2019 |
Butterfield JSS, Biswas M, Shirley JL, Kumar SRP, Sherman A, Terhorst C, Ling C, Herzog R. TLR9-activating CpG-B ODN but not TLR7 Agonists Trigger Antibody Formation to Factor IX in Muscle Gene Transfer. Human Gene Therapy Methods. PMID 31140323 DOI: 10.1089/Hgtb.2019.013 |
0.411 |
|
| 2019 |
Wang N, Yigit B, van der Poel CE, Cuenca M, Carroll MC, Herzog RW, Engel P, Terhorst C. The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease. Frontiers in Immunology. 10: 831. PMID 31057553 DOI: 10.3389/Fimmu.2019.00831 |
0.437 |
|
| 2019 |
Herzog RW, Kuteyeva V, Saboungi R, Terhorst C, Biswas M. Reprogrammed CD4 T Cells That Express FoxP3 Control Inhibitory Antibody Formation in Hemophilia A Mice. Frontiers in Immunology. 10: 274. PMID 30842776 DOI: 10.3389/Fimmu.2019.00274 |
0.51 |
|
| 2019 |
Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods. Methods in Molecular Biology (Clifton, N.J.). 1950: 333-360. PMID 30783984 DOI: 10.1007/978-1-4939-9139-6_20 |
0.421 |
|
| 2018 |
Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood. PMID 30559260 DOI: 10.1182/Blood-2018-07-820720 |
0.529 |
|
| 2018 |
Sherman A, Biswas M, Herzog RW. Tolerance induction in hemophilia: innovation and accomplishments. Current Opinion in Hematology. PMID 29994897 DOI: 10.1097/Moh.0000000000000446 |
0.381 |
|
| 2018 |
Xiao W, Gao G, Ling C, Herzog RW, Xiao X, Samulski RJ. Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates. Nature Medicine. PMID 29867233 DOI: 10.1038/S41591-018-0062-2 |
0.382 |
|
| 2018 |
Biswas M, Kumar SRP, Terhorst C, Herzog RW. Gene Therapy With Regulatory T Cells: A Beneficial Alliance. Frontiers in Immunology. 9: 554. PMID 29616042 DOI: 10.3389/Fimmu.2018.00554 |
0.544 |
|
| 2018 |
Corti M, Cleaver B, Clement N, Wang G, Benson J, Tarantal A, Herzog R, Byrne B. Enabling redosing of AAV by immune management in Pompe disease: Preclinical to clinical studies Molecular Genetics and Metabolism. 123: S34. DOI: 10.1016/J.Ymgme.2017.12.067 |
0.322 |
|
| 2017 |
Sherman A, Biswas M, Herzog RW. Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. Frontiers in Immunology. 8: 1604. PMID 29225598 DOI: 10.3389/Fimmu.2017.01604 |
0.531 |
|
| 2017 |
Corti M, Liberati C, Smith BK, Lawson LA, Tuna IS, Conlon TJ, Erger KE, Islam S, Herzog R, Fuller DD, Collins S, Byrne BJ. Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in children affected by Pompe Disease. Human Gene Therapy. Clinical Development. PMID 29160099 DOI: 10.1089/humc.2017.146 |
0.32 |
|
| 2017 |
Kwon KC, Sherman A, Chang WJ, Kamesh A, Biswas M, Herzog RW, Daniell H. Expression and assembly of largest foreign protein in chloroplasts: Oral delivery of human FVIII made in lettuce chloroplasts robustly suppresses inhibitor formation in hemophilia A mice. Plant Biotechnology Journal. PMID 29106782 DOI: 10.1111/Pbi.12859 |
0.45 |
|
| 2017 |
Herzog RW, Cooper M, Perrin GQ, Biswas M, Martino AT, Morel L, Terhorst C, Hoffman BE. Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer. Cellular Immunology. PMID 28888664 DOI: 10.1016/J.Cellimm.2017.07.012 |
0.507 |
|
| 2017 |
Herzog RW. Complexity of immune responses to AAV transgene products - Example of factor IX. Cellular Immunology. PMID 28645365 DOI: 10.1016/J.Cellimm.2017.05.006 |
0.5 |
|
| 2017 |
Palaschak B, Marsic D, Herzog RW, Zolotukhin S, Markusic DM. An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8(+) T Cells. Molecular Therapy. Methods & Clinical Development. 5: 142-152. PMID 28480313 DOI: 10.1016/J.Omtm.2017.04.004 |
0.554 |
|
| 2017 |
Wang X, Herzog RW, Byrne BJ, Kumar SRP, Zhou Q, Buchholz CJ, Biswas M. Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells. Molecular Therapy. Methods & Clinical Development. 5: 76-82. PMID 28480307 DOI: 10.1016/J.Omtm.2017.03.005 |
0.505 |
|
| 2017 |
Rogers GL, Shirley JL, Zolotukhin I, Kumar SRP, Sherman A, Perrin GQ, Hoffman BE, Srivastava A, Basner-Tschakarjan E, Wallet MA, Terhorst C, Biswas M, Herzog RW. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T cells. Blood. 129: 3184-3195. PMID 28468798 DOI: 10.1182/Blood-2016-11-751040 |
0.468 |
|
| 2017 |
Markusic DM, Nichols TC, Merricks EP, Palaschak B, Zolotukhin I, Marsic D, Zolotukhin S, Srivastava A, Herzog RW. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. Journal of Translational Medicine. 15: 94. PMID 28460646 DOI: 10.1186/S12967-017-1200-1 |
0.502 |
|
| 2017 |
Kumar SR, Hoffman BE, Terhorst C, de Jong YP, Herzog RW. The Balance between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 880-891. PMID 28284982 DOI: 10.1016/J.Ymthe.2017.02.014 |
0.482 |
|
| 2017 |
Herzog RW, Nichols TC, Su J, Zhang B, Sherman A, Merricks EP, Raymer R, Perrin GQ, Häger M, Wiinberg B, Daniell H. Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 512-522. PMID 28153098 DOI: 10.1016/J.Ymthe.2016.11.009 |
0.418 |
|
| 2017 |
Herzog RW. Driving the hemophilia tolerance CAR. Blood. 129: 142-144. PMID 28082293 DOI: 10.1182/Blood-2016-11-753160 |
0.394 |
|
| 2017 |
Biswas M, Rogers GL, Sherman A, Byrne BJ, Markusic DM, Jiang H, Herzog RW. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Thrombosis and Haemostasis. 117: 33-43. PMID 27683758 DOI: 10.1160/Th16-05-0404 |
0.442 |
|
| 2017 |
Herzog RW, Sherman A, Kwon K, Chang W, Daniell H. Lettuce Plants Expressing High Levels of Factor VIII Antigen in the Chloroplast for Oral Tolerance in Hemophilia a Blood. 130: 362-362. DOI: 10.1182/Blood.V130.Suppl_1.362.362 |
0.465 |
|
| 2016 |
Perrin GQ, Zolotukhin I, Sherman A, Biswas M, de Jong YP, Terhorst C, Davidoff AM, Herzog RW. Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer. Molecular Therapy. Methods & Clinical Development. 3: 16083. PMID 27933310 DOI: 10.1038/Mtm.2016.83 |
0.482 |
|
| 2016 |
Zolotukhin I, Markusic DM, Palaschak B, Hoffman BE, Srikanthan MA, Herzog RW. Potential for cellular stress response to hepatic factor VIII expression from AAV vector. Molecular Therapy. Methods & Clinical Development. 3: 16063. PMID 27738644 DOI: 10.1038/Mtm.2016.63 |
0.483 |
|
| 2016 |
Herzog RW. A Cure For Hemophilia: the Promise Becomes a Reality. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 1503-4. PMID 27687132 DOI: 10.1038/Mt.2016.169 |
0.525 |
|
| 2016 |
Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Molecular Therapy. Methods & Clinical Development. 3: 16034. PMID 27257611 DOI: 10.1038/Mtm.2016.34 |
0.598 |
|
| 2016 |
Herzog RW. Expanded Opportunities for Methods and Clinical Development. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 655-6. PMID 27081714 DOI: 10.1038/Mt.2016.44 |
0.426 |
|
| 2016 |
Vercauteren K, Hoffman BE, Zolotukhin I, Keeler GD, Xiao JW, Basner-Tschakarjan E, High KA, Ertl HC, Rice CM, Srivastava A, de Jong YP, Herzog RW. Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 1042-1049. PMID 27019999 DOI: 10.1038/Mt.2016.61 |
0.582 |
|
| 2016 |
Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ. Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy. Methods & Clinical Development. 3: 15053. PMID 26858964 DOI: 10.1038/Mtm.2015.53 |
0.783 |
|
| 2016 |
Xiao Y, Kwon KC, Hoffman BE, Kamesh A, Jones NT, Herzog RW, Daniell H. Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells. Biomaterials. 80: 68-79. PMID 26706477 DOI: 10.1016/J.Biomaterials.2015.11.051 |
0.387 |
|
| 2016 |
Doerfler PA, Todd AG, Clément N, Falk DJ, Nayak S, Herzog RW, Byrne BJ. Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Human Gene Therapy. 27: 43-59. PMID 26603344 DOI: 10.1089/Hum.2015.103 |
0.797 |
|
| 2016 |
Wang X, Terhorst C, Herzog RW. In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cellular Immunology. 301: 18-29. PMID 26454643 DOI: 10.1016/J.Cellimm.2015.10.001 |
0.501 |
|
| 2016 |
Markusic D, Palaschak B, Zolotukhin I, Herzog R. 688. Supplemental Immune Suppression Is Required for AAV-F8 ITI in Hemophilia A Mice with Pre-Existing Inhibitors Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33496-7 |
0.526 |
|
| 2016 |
Corti M, Cleaver B, Clement N, Conlon T, Faris K, Wang G, Benson J, Tarantal A, Fuller D, Herzog R, Byrne BJ. 472. Evaluation of Re-Administration of a Recombinant Adeno-Associated Vector Expressing Acid-Alpha-Glucosidase (rAAV9-DES-hGAA) in Pompe Disease: Preclinical to Clinical Planning Molecular Therapy. 24: S186-S187. DOI: 10.1016/S1525-0016(16)33281-6 |
0.459 |
|
| 2016 |
Kumar S, Hoffman BE, Herzog RW. 79. Vector Dose Delineates Between Chronic, Non-Functional CD8+ T Cell Response and Tolerance to the Transgene Product Upon Liver Gene Transfer Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)32888-X |
0.518 |
|
| 2016 |
Shirley JL, Rogers GL, Biswas M, Herzog RW. 78. Distinct Roles of Dendritic Cell Subsets in Innate Immune Sensing and Cross-Presentation of AAV Capsid In Vivo Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)32887-8 |
0.519 |
|
| 2015 |
Corti M, Cleaver B, Clément N, Conlon TJ, Faris KJ, Wang G, Benson J, Tarantal AF, Fuller D, Herzog RW, Byrne BJ. Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning. Human Gene Therapy. Clinical Development. 26: 185-93. PMID 26390092 DOI: 10.1089/Humc.2015.068 |
0.458 |
|
| 2015 |
Herzog RW. Hemophilia Gene Therapy: Caught Between a Cure and an Immune Response. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1411-2. PMID 26321180 DOI: 10.1038/Mt.2015.135 |
0.511 |
|
| 2015 |
Su J, Zhu L, Sherman A, Wang X, Lin S, Kamesh A, Norikane JH, Streatfield SJ, Herzog RW, Daniell H. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials. 70: 84-93. PMID 26302233 DOI: 10.1016/J.Biomaterials.2015.08.004 |
0.402 |
|
| 2015 |
Biswas M, Terhorst C, Herzog RW. Treg: tolerance vs immunity. Oncotarget. 6: 19956-7. PMID 26119156 DOI: 10.18632/Oncotarget.4648 |
0.451 |
|
| 2015 |
Su J, Sherman A, Doerfler PA, Byrne BJ, Herzog RW, Daniell H. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnology Journal. 13: 1023-32. PMID 26053072 DOI: 10.1111/Pbi.12413 |
0.418 |
|
| 2015 |
Doerfler PA, Nayak S, Herzog RW, Morel L, Byrne BJ. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clinical Immunology (Orlando, Fla.). 158: 140-7. PMID 25842186 DOI: 10.1016/J.Clim.2015.03.022 |
0.75 |
|
| 2015 |
Biswas M, Sarkar D, Kumar SR, Nayak S, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood. 125: 2937-47. PMID 25833958 DOI: 10.1182/Blood-2014-09-599266 |
0.766 |
|
| 2015 |
Herzog RW. Molecular therapy: at the cutting edge of methodology and clinical development. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 409-10. PMID 25720691 DOI: 10.1038/Mt.2015.23 |
0.434 |
|
| 2015 |
Wang X, Su J, Sherman A, Rogers GL, Liao G, Hoffman BE, Leong KW, Terhorst C, Daniell H, Herzog RW. Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood. 125: 2418-27. PMID 25700434 DOI: 10.1182/Blood-2014-08-597070 |
0.511 |
|
| 2015 |
Rogers GL, Suzuki M, Zolotukhin I, Markusic DM, Morel LM, Lee B, Ertl HC, Herzog RW. Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer. Journal of Innate Immunity. 7: 302-14. PMID 25612611 DOI: 10.1159/000369273 |
0.478 |
|
| 2015 |
Rogers GL, Herzog RW. Gene therapy for hemophilia. Frontiers in Bioscience (Landmark Edition). 20: 556-603. PMID 25553466 DOI: 10.2741/4324 |
0.409 |
|
| 2015 |
Herzog RW, Hoffman BE, Zolotukhin I, High KA, Srivastava A, de Jong YP, Vercauteren K, Xiao J. AAV3 Capsid Is Superior for In Vivo Gene Transfer to Human Hepatocytes Compared to Serotypes 5 and 8 in a Mouse/Human Chimeric Model Blood. 126: 4418-4418. DOI: 10.1182/Blood.V126.23.4418.4418 |
0.575 |
|
| 2015 |
Herzog RW, Perrin GQ. Hepatic AAV Gene Transfer of Cytoplasmic Transgene Induces Transgene Product-Specific T Cell Activation Initially in the Liver and Celiac Lymph Node Preceding Treg Induction Blood. 126: 3241-3241. DOI: 10.1182/Blood.V126.23.3241.3241 |
0.472 |
|
| 2015 |
Zolotukhin I, Palaschak B, Markusic DM, Herzog R. Clotting Factor VIII Overexpression Shows Signs of ER Stress but Does Not Cause Toxicity upon Gene Transfer Blood. 126: 3238-3238. DOI: 10.1182/Blood.V126.23.3238.3238 |
0.336 |
|
| 2015 |
Herzog RW, Su J, Zhu L, Wang X, Lin S, Kamesh A, Daniell H. Factor IX Expressed in Lettuce Chloroplasts Induces Oral Tolerance in Hemophilia B Mice Blood. 126: 292-292. DOI: 10.1182/Blood.V126.23.292.292 |
0.497 |
|
| 2015 |
Wang Q, Firrman J, Pokiniewski KA, Cao W, Wei H, Herzog R, Xiao W. The Light Chain of Rat Factor VIII Confers Its Superior Cofactor Activity Blood. 126: 2038-2038. DOI: 10.1182/Blood.V126.23.2038.2038 |
0.412 |
|
| 2015 |
Rogers GL, Zolotukhin I, Herzog RW. 519. Unique Role of the TLR9-MyD88 Signaling Pathway in Dendritic Cells in AAV Capsid-Specific CD8+ T Cell Activation Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34128-4 |
0.487 |
|
| 2015 |
Doerfler PA, Todd AG, Clément N, Falk DJ, Herzog RW, Byrne BJ. 368. Simultaneous Delivery of Dual AAV9 Vectors Induces Immune Tolerance and Correction of Pompe Disease Pathology Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33977-6 |
0.501 |
|
| 2015 |
Biswas M, Sarkar D, Nayak S, Kumar SR, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. 293. Optimal In Vivo Treg Induction and Suppression of Immune Responses By Synergistic Use of Rapamycin and FLT3 Ligand Molecular Therapy. 23: S118. DOI: 10.1016/S1525-0016(16)33902-8 |
0.789 |
|
| 2015 |
Perrin GQ, Zolotukhin I, Herzog RW. 40. Transgene Product-Specific Treg Are Initially Induced in the Celiac Lymph Node During Tolerance Induction By Hepatic AAV Gene Transfer Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33645-0 |
0.495 |
|
| 2014 |
Sack BK, Herzog RW, Terhorst C, Markusic DM. Development of Gene Transfer for Induction of Antigen-specific Tolerance. Molecular Therapy. Methods & Clinical Development. 1: 14013. PMID 25558460 DOI: 10.1038/Mtm.2014.13 |
0.776 |
|
| 2014 |
Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, Conlon T, Clément N, Erger K, Lavassani E, Green M, Doerfler P, Herzog R, Byrne B. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Molecular Therapy. Methods & Clinical Development. 1. PMID 25541616 DOI: 10.1038/Mtm.2014.33 |
0.796 |
|
| 2014 |
Sarkar D, Biswas M, Liao G, Seay HR, Perrin GQ, Markusic DM, Hoffman BE, Brusko TM, Terhorst C, Herzog RW. Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia. Molecular Therapy. Methods & Clinical Development. 1. PMID 25364772 DOI: 10.1038/Mtm.2014.30 |
0.522 |
|
| 2014 |
Marsic D, Govindasamy L, Currlin S, Markusic DM, Tseng YS, Herzog RW, Agbandje-McKenna M, Zolotukhin S. Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1900-9. PMID 25048217 DOI: 10.1038/Mt.2014.139 |
0.334 |
|
| 2014 |
Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. Plos One. 9: e98336. PMID 24897114 DOI: 10.1371/Journal.Pone.0098336 |
0.763 |
|
| 2014 |
Markusic DM, Herzog RW. A David promoter with Goliath strength. Blood. 123: 3068-9. PMID 24832942 DOI: 10.1182/Blood-2014-04-565507 |
0.404 |
|
| 2014 |
Sherman A, Su J, Lin S, Wang X, Herzog RW, Daniell H. Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood. 124: 1659-68. PMID 24825864 DOI: 10.1182/Blood-2013-10-528737 |
0.494 |
|
| 2014 |
Wang X, Moghimi B, Zolotukhin I, Morel LM, Cao O, Herzog RW. Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1139-1150. PMID 24609143 DOI: 10.1038/Mt.2014.43 |
0.478 |
|
| 2014 |
Sherman A, Schlachterman A, Cooper M, Merricks EP, Raymer RA, Bellinger DA, Herzog RW, Nichols TC. Portal vein delivery of viral vectors for gene therapy for hemophilia. Methods in Molecular Biology (Clifton, N.J.). 1114: 413-26. PMID 24557919 DOI: 10.1007/978-1-62703-761-7_27 |
0.452 |
|
| 2014 |
Liao G, O'Keeffe MS, Wang G, van Driel B, de Waal Malefyt R, Reinecker HC, Herzog RW, Terhorst C. Glucocorticoid-Induced TNF Receptor Family-Related Protein Ligand is Requisite for Optimal Functioning of Regulatory CD4(+) T Cells. Frontiers in Immunology. 5: 35. PMID 24550919 DOI: 10.3389/Fimmu.2014.00035 |
0.446 |
|
| 2014 |
Rogers GL, Herzog RW. One microRNA controls both angiogenesis and TLR-mediated innate immunity to nucleic acids. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 249-250. PMID 24487566 DOI: 10.1038/Mt.2013.299 |
0.383 |
|
| 2014 |
Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. Journal of Translational Medicine. 12: 25. PMID 24460861 DOI: 10.1186/1479-5876-12-25 |
0.48 |
|
| 2014 |
Liao G, van Driel B, Magelky E, O'Keeffe MS, de Waal Malefyt R, Engel P, Herzog RW, Mizoguchi E, Bhan AK, Terhorst C. Glucocorticoid-induced TNF receptor family-related protein ligand regulates the migration of monocytes to the inflamed intestine. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 474-84. PMID 24107315 DOI: 10.1096/Fj.13-236505 |
0.337 |
|
| 2014 |
Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Antibody responses to varying doses of rhGAA in null mutation (n = 6) or P545L mutant mice (n = 5). Plos One. DOI: 10.1371/Journal.Pone.0098336.G003 |
0.71 |
|
| 2014 |
Rogers GL, Herzog RW. TLR9 and Dendritic Cells Are Required for CD8+ T Cell Responses to the AAV Capsid Blood. 124: 552-552. DOI: 10.1182/Blood.V124.21.552.552 |
0.47 |
|
| 2013 |
Zolotukhin I, Luo D, Gorbatyuk O, Hoffman B, Warrington K, Herzog R, Harrison J, Cao O. Improved Adeno-associated Viral Gene Transfer to Murine Glioma. Journal of Genetic Syndromes & Gene Therapy. 4. PMID 24319629 DOI: 10.4172/2157-7412.1000133 |
0.453 |
|
| 2013 |
Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA, High KA, Herzog RW. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. Embo Molecular Medicine. 5: 1698-709. PMID 24106230 DOI: 10.1002/Emmm.201302859 |
0.816 |
|
| 2013 |
Hoffman BE, Herzog RW. Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1648-50. PMID 24008618 DOI: 10.1038/Mt.2013.176 |
0.507 |
|
| 2013 |
Chakraborty S, Christoforou N, Fattahi A, Herzog RW, Leong KW. A robust strategy for negative selection of Cre-loxP recombination-based excision of transgenes in induced pluripotent stem cells. Plos One. 8: e64342. PMID 23717601 DOI: 10.1371/Journal.Pone.0064342 |
0.388 |
|
| 2013 |
Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. The Journal of Pediatrics. 163: 847-54.e1. PMID 23601496 DOI: 10.1016/J.Jpeds.2013.03.002 |
0.735 |
|
| 2013 |
Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, ... ... Herzog RW, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/Mt.2013.4 |
0.574 |
|
| 2013 |
Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, Ostrov DA, Srivastava A, Ertl HC, Terhorst C, High KA, Mingozzi F, Herzog RW. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood. 121: 2224-33. PMID 23325831 DOI: 10.1182/Blood-2012-10-460733 |
0.631 |
|
| 2013 |
Suzuki M, Bertin TK, Rogers GL, Cela RG, Zolotukhin I, Palmer DJ, Ng P, Herzog RW, Lee B. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 796-805. PMID 23319058 DOI: 10.1038/Mt.2012.277 |
0.408 |
|
| 2013 |
Wang X, Sherman A, Liao G, Leong KW, Daniell H, Terhorst C, Herzog RW. Mechanism of oral tolerance induction to therapeutic proteins. Advanced Drug Delivery Reviews. 65: 759-73. PMID 23123293 DOI: 10.1016/J.Addr.2012.10.013 |
0.425 |
|
| 2013 |
Kwon KC, Verma D, Singh ND, Herzog R, Daniell H. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Advanced Drug Delivery Reviews. 65: 782-99. PMID 23099275 DOI: 10.1016/J.Addr.2012.10.005 |
0.359 |
|
| 2013 |
Herzog RW. Self-Complementary AAV Vectors Delivered Intramuscularly Do Not Break Tolerance In a Partial Knockout Model Of Hemophilia B Blood. 122: 4209-4209. DOI: 10.1182/Blood.V122.21.4209.4209 |
0.552 |
|
| 2013 |
Wang X, Sherman A, Su J, Daniell H, Herzog RW. Mechanism Of Oral Tolerance Induced By Bioencapsulated Coagulation Factor IX In Hemophilia B Mice Blood. 122: 30-30. DOI: 10.1182/Blood.V122.21.30.30 |
0.508 |
|
| 2012 |
Wynn T, Slayton WB, Herzog RW. The Need for Gene Therapy for the Effective Treatment of Hemophilia. Journal of Genetic Syndromes & Gene Therapy. PMID 25309817 DOI: 10.4172/2157-7412.S1-016 |
0.399 |
|
| 2012 |
Markusic DM, Herzog RW. Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. Journal of Genetic Syndromes & Gene Therapy. 1: 1-9. PMID 23565343 DOI: 10.4172/2157-7412.S1-009 |
0.499 |
|
| 2012 |
Zhong L, Jayandharan GR, Aslanidi GV, Zolotukhin S, Herzog RW, Srivastava A. Development of Novel Recombinant AAV Vectors and Strategies for the Potential Gene Therapy of Hemophilia. Journal of Genetic Syndromes & Gene Therapy. PMID 23264889 DOI: 10.4172/2157-7412.S1-008 |
0.478 |
|
| 2012 |
Herzog RW, Ostrov DA. Immunology. A decorated virus cannot hide. Science (New York, N.Y.). 338: 748-9. PMID 23139318 DOI: 10.1126/Science.1230342 |
0.326 |
|
| 2012 |
Perrin GQ, Herzog RW. Making dendritic cells that turn immune responses off. Human Gene Therapy. 23: ix-xi. PMID 22822900 DOI: 10.1089/Hum.2012.2514 |
0.362 |
|
| 2012 |
Hoffman BE, Ertl HC, Terhorst C, High KA, Herzog RW. Gene therapy research at the frontiers of viral immunology. Frontiers in Microbiology. 3: 182. PMID 22783235 DOI: 10.3389/Fmicb.2012.00182 |
0.652 |
|
| 2012 |
Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, Herzog RW. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. Plos One. 7: e37671. PMID 22655063 DOI: 10.1371/Journal.Pone.0037671 |
0.799 |
|
| 2012 |
Nayak S, Sivakumar R, Cao O, Daniell H, Byrne BJ, Herzog RW. Mapping the T helper cell response to acid α-glucosidase in Pompe mice. Molecular Genetics and Metabolism. 106: 189-95. PMID 22494547 DOI: 10.1016/J.Ymgme.2012.03.009 |
0.773 |
|
| 2012 |
Herzog RW. Seeing eye to eye with gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 687-8. PMID 22472974 DOI: 10.1038/Mt.2012.43 |
0.405 |
|
| 2012 |
Liao G, Detre C, Berger SB, Engel P, de Waal Malefyt R, Herzog RW, Bhan AK, Terhorst C. Glucocorticoid-induced tumor necrosis factor receptor family-related protein regulates CD4(+)T cell-mediated colitis in mice. Gastroenterology. 142: 582-591.e8. PMID 22155173 DOI: 10.1053/J.Gastro.2011.11.031 |
0.397 |
|
| 2012 |
Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE. Animal models of hemophilia. Progress in Molecular Biology and Translational Science. 105: 151-209. PMID 22137432 DOI: 10.1016/B978-0-12-394596-9.00006-8 |
0.437 |
|
| 2012 |
Wang X, Moghimi B, Zolotukhin I, Cao O, Herzog RW. Immune Tolerance Induction to Factor IX Through B Cell Gene Transfer – Delineating Between Tolerogenic and Immunogenic B Cells. Blood. 120: 3156-3156. DOI: 10.1182/Blood.V120.21.3156.3156 |
0.539 |
|
| 2012 |
Sarkar D, Liao G, Terhorst C, Herzog RW. Synergistic Effect of Flt3L and Rapamycin On Immune Tolerance Induction Via Plasmacytoid Dendritic Cells and Treg. Blood. 120: 2209-2209. DOI: 10.1182/Blood.V120.21.2209.2209 |
0.482 |
|
| 2012 |
Markusic DM, Martino AT, Mingozzi F, High KA, Herzog RW. In Vivo Model to Evaluate Loss of Liver-Derived Factor IX Expression Caused by AAV Capsid-Specific CD8+ T Cells Blood. 120: 2046-2046. DOI: 10.1182/Blood.V120.21.2046.2046 |
0.666 |
|
| 2012 |
Herzog RW, Verma D, Wang X, Sherman A, Lin S, Daniell H. Suppression of Inhibitor Formation Against Factor VIII in Hemophilia A Mice by Oral Delivery of Bioencapsulated Antigen Blood. 120: 14-14. DOI: 10.1182/Blood.V120.21.14.14 |
0.43 |
|
| 2012 |
Sarkar D, Markusic DM, Terhorst C, Brusko T, Herzog RW. Suppression of Inhibitor Formation in Protein and Gene Therapy for Hemophilia Using Ex Vivo Expanded Treg Blood. 120: 13-13. DOI: 10.1182/Blood.V120.21.13.13 |
0.547 |
|
| 2011 |
Moghimi B, Zolotukhin I, Sack BK, Herzog RW, Cao O. High Efficiency Ex Vivo Gene Transfer to Primary Murine B Cells Using Plasmid or Viral Vectors. Journal of Genetic Syndromes & Gene Therapy. 2. PMID 23565344 DOI: 10.4172/2157-7412.1000103 |
0.738 |
|
| 2011 |
Nayak S, Sarkar D, Perrin GQ, Moghimi B, Hoffman BE, Zhou S, Byrne BJ, Herzog RW. Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Frontiers in Microbiology. 2: 244. PMID 22279442 DOI: 10.3389/Fmicb.2011.00244 |
0.816 |
|
| 2011 |
Herzog RW, Davidoff AM, Markusic DM, Nathwani AC. AAV vector biology in primates: finding the missing link? Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1923-4. PMID 22051598 DOI: 10.1038/Mt.2011.218 |
0.528 |
|
| 2011 |
Martino AT, Herzog RW, Anegon I, Adjali O. Measuring immune responses to recombinant AAV gene transfer. Methods in Molecular Biology (Clifton, N.J.). 807: 259-72. PMID 22034034 DOI: 10.1007/978-1-61779-370-7_11 |
0.502 |
|
| 2011 |
Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A, Herzog RW. Innate Immune Responses to AAV Vectors. Frontiers in Microbiology. 2: 194. PMID 21954398 DOI: 10.3389/Fmicb.2011.00194 |
0.448 |
|
| 2011 |
Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Journal of Thrombosis and Haemostasis : Jth. 9: 1524-33. PMID 21585650 DOI: 10.1111/J.1538-7836.2011.04351.X |
0.806 |
|
| 2011 |
Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ, Clement N, Cleaver BD, Cloutier DA, Porvasnik SL, Islam S, Elmallah MK, Martin A, et al. Pompe disease gene therapy. Human Molecular Genetics. 20: R61-8. PMID 21518733 DOI: 10.1093/Hmg/Ddr174 |
0.731 |
|
| 2011 |
Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 117: 6459-68. PMID 21474674 DOI: 10.1182/Blood-2010-10-314518 |
0.489 |
|
| 2011 |
Hoffman BE, Martino AT, Sack BK, Cao O, Liao G, Terhorst C, Herzog RW. Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1263-72. PMID 21386826 DOI: 10.1038/Mt.2011.33 |
0.745 |
|
| 2011 |
Jayandharan GR, Aslanidi G, Martino AT, Jahn SC, Perrin GQ, Herzog RW, Srivastava A. Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proceedings of the National Academy of Sciences of the United States of America. 108: 3743-8. PMID 21321191 DOI: 10.1073/Pnas.1012753108 |
0.384 |
|
| 2011 |
Markusic D, Herzog RW. Hepatic Gene Transfer of Factor IX Reverses Inhibitors and Protects From Anaphylaxis in a Murine Hemophilia B Model Blood. 118: 669-669. DOI: 10.1182/Blood.V118.21.669.669 |
0.515 |
|
| 2010 |
Herzog RW. Gene therapy for SCID-X1: round 2. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1891. PMID 21042293 DOI: 10.1038/Mt.2010.228 |
0.471 |
|
| 2010 |
Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C, Zolotukhin I, Ma W, Zolotukhin S, Srivastava A, Zhong L. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 2048-56. PMID 20736929 DOI: 10.1038/Mt.2010.172 |
0.466 |
|
| 2010 |
Herzog RW. Hepatic AAV gene transfer and the immune system: friends or foes? Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1063-6. PMID 20514031 DOI: 10.1038/Mt.2010.96 |
0.518 |
|
| 2010 |
Verma D, Moghimi B, LoDuca PA, Singh HD, Hoffman BE, Herzog RW, Daniell H. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proceedings of the National Academy of Sciences of the United States of America. 107: 7101-6. PMID 20351275 DOI: 10.1073/Pnas.0912181107 |
0.483 |
|
| 2010 |
Herzog RW, Cao O, Srivastava A. Two decades of clinical gene therapy--success is finally mounting. Discovery Medicine. 9: 105-11. PMID 20193635 |
0.359 |
|
| 2010 |
Liao G, Nayak S, Regueiro JR, Berger SB, Detre C, Romero X, de Waal Malefyt R, Chatila TA, Herzog RW, Terhorst C. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells. International Immunology. 22: 259-70. PMID 20139172 DOI: 10.1093/Intimm/Dxq001 |
0.776 |
|
| 2010 |
Nayak S, Herzog RW. Progress and prospects: Immune responses to viral vectors Gene Therapy. 17: 295-304. PMID 19907498 DOI: 10.1038/Gt.2009.148 |
0.783 |
|
| 2010 |
Jayandharan GR, Zhong L, Sack BK, Rivers AE, Li M, Li B, Herzog RW, Srivastava A. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Human Gene Therapy. 21: 271-83. PMID 19788390 DOI: 10.1089/Hum.2009.100 |
0.734 |
|
| 2010 |
Sack B, Moghimi B, Byrne B, Herzog RW. Anti-CD20 to Control Antibody Formation Against FVIII In Gene and Protein Replacement Therapy Blood. 116: 711-711. DOI: 10.1182/Blood.V116.21.711.711 |
0.76 |
|
| 2010 |
Nayak S, Moghimi B, Herzog RW. Strategies to Prevent or Reverse Immune Responses Against Factor In Gene Replacement for Hemophilia B. Blood. 116: 3761-3761. DOI: 10.1182/Blood.V116.21.3761.3761 |
0.821 |
|
| 2010 |
Martino AT, Suzuki M, Markusic D, Zolotukhin I, Muruve DA, Lee B, Herzog RW. Self-Complementary AAV Vectors Cause a Substantially Heightened TLR9-Dependent Innate Immune Response In the Liver Blood. 116: 252-252. DOI: 10.1182/Blood.V116.21.252.252 |
0.475 |
|
| 2010 |
Markusic D, Nayak S, Herzog RW. Humoral and Anaphylactic Responses to Factor IX In Murine Hemophilia B Are Genotype Dependent and Can Be Reversed by Hepatic Gene Transfer Blood. 116: 2202-2202. DOI: 10.1182/Blood.V116.21.2202.2202 |
0.805 |
|
| 2010 |
Moghimi B, Sack B, Cao O, Herzog RW. Tolerance Induction to B Domain-Deleted and Full-Length F.VIII by Co-Administration with Rapamycin Blood. 116: 21-21. DOI: 10.1182/Blood.V116.21.21.21 |
0.767 |
|
| 2009 |
Wasserfall CH, Herzog RW. Gene therapy approaches to induce tolerance in autoimmunity by reshaping the immune system. Current Opinion in Investigational Drugs (London, England : 2000). 10: 1143-50. PMID 19876782 |
0.386 |
|
| 2009 |
Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Current Opinion in Molecular Therapeutics. 11: 493-503. PMID 19806497 |
0.746 |
|
| 2009 |
Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, Byrne BJ, Terhorst C, Herzog RW. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. Plos One. 4: e6376. PMID 19652717 DOI: 10.1371/Journal.Pone.0006376 |
0.787 |
|
| 2009 |
Cao O, Loduca PA, Herzog RW. Role of regulatory T cells in tolerance to coagulation factors. Journal of Thrombosis and Haemostasis. 7: 88-91. PMID 19630776 DOI: 10.1111/J.1538-7836.2009.03417.X |
0.487 |
|
| 2009 |
Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, Ertl HC, High KA, Herzog RW. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1733-42. PMID 19603001 DOI: 10.1038/Mt.2009.159 |
0.828 |
|
| 2009 |
Nayak S, Cao O, Hoffman BE, Cooper M, Zhou S, Atkinson MA, Herzog RW. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells Journal of Thrombosis and Haemostasis. 7: 1523-1532. PMID 19583824 DOI: 10.1111/J.1538-7836.2009.03548.X |
0.794 |
|
| 2009 |
LoDuca PA, Hoffman BE, Herzog RW. Hepatic gene transfer as a means of tolerance induction to transgene products. Current Gene Therapy. 9: 104-14. PMID 19355868 DOI: 10.2174/156652309787909490 |
0.506 |
|
| 2009 |
Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Human Gene Therapy. 20: 767-76. PMID 19309290 DOI: 10.1089/Hum.2008.161 |
0.801 |
|
| 2009 |
Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, van Ginkel FW, High KA, Lothrop CD. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 113: 797-806. PMID 18957684 DOI: 10.1182/Blood-2008-10-181479 |
0.603 |
|
| 2009 |
Herzog RW, Verma D, Moghimi B, Singh HD, LoDuca PA, Daniell H. Oral Delivery of Bioencapsulated Factor IX Protects From Inhibitor Formation and Anaphylaxis in Protein Replacement Therapy for Hemophilia B. Blood. 114: 222-222. DOI: 10.1182/Blood.V114.22.222.222 |
0.492 |
|
| 2008 |
Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology. 381: 194-202. PMID 18834608 DOI: 10.1016/J.Virol.2008.08.027 |
0.352 |
|
| 2008 |
Hoffman BE, Herzog RW. Coaxing the liver into preventing autoimmune disease in the brain. The Journal of Clinical Investigation. 118: 3271-3. PMID 18802483 DOI: 10.1172/Jci37079 |
0.419 |
|
| 2008 |
Cao O, Herzog RW. TLR3 signaling does not affect organ-specific immune responses to factor IX in AAV gene therapy. Blood. 112: 910-1. PMID 18650463 DOI: 10.1182/Blood-2008-02-137992 |
0.508 |
|
| 2008 |
Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proceedings of the National Academy of Sciences of the United States of America. 105: 7827-32. PMID 18511559 DOI: 10.1073/Pnas.0802866105 |
0.424 |
|
| 2008 |
Herzog RW, Arruda VR. Substantial immune suppression required in gene therapy for muscular dystrophy? Neuromuscular Disorders : Nmd. 18: 83-4. PMID 18365340 DOI: 10.1016/J.Nmd.2007.08.007 |
0.457 |
|
| 2008 |
Tai SJ, Herzog RW, Margaritis P, Arruda VR, Chu K, Golden JA, Labosky PA, High KA. A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. Journal of Thrombosis and Haemostasis : Jth. 6: 339-45. PMID 18036190 DOI: 10.1111/J.1538-7836.2007.02849.X |
0.562 |
|
| 2008 |
Nayak S, Hoffman B, Cooper M, Atkinson M, Cao O, Herzog RW. A Prophylactic Protocol for the Prevention of Inhibitor Formation in Gene Therapy for Hemophilia B by Shifting the Balance from An Effector to a Regulatory T Cell Response Blood. 112: 3531-3531. DOI: 10.1182/Blood.V112.11.3531.3531 |
0.776 |
|
| 2007 |
Cao O, Furlan-Freguia C, Arruda VR, Herzog RW. Emerging role of regulatory T cells in gene transfer. Current Gene Therapy. 7: 381-90. PMID 17979684 DOI: 10.2174/156652307782151506 |
0.539 |
|
| 2007 |
Herzog RW. Gene therapy and the immune system. Current Gene Therapy. 7: 296. PMID 17979675 DOI: 10.2174/156652307782151470 |
0.445 |
|
| 2007 |
Hoffman BE, Dobrzynski E, Wang L, Hirao L, Mingozzi F, Cao O, Herzog RW. Muscle as a target for supplementary factor IX gene transfer. Human Gene Therapy. 18: 603-13. PMID 17594244 DOI: 10.1089/Hum.2007.042 |
0.548 |
|
| 2007 |
Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 110: 1132-40. PMID 17438084 DOI: 10.1182/Blood-2007-02-073304 |
0.78 |
|
| 2007 |
Herzog RW. Immune responses to AAV capsid: are mice not humans after all? Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 649-50. PMID 17372595 DOI: 10.1038/Sj.Mt.6300123 |
0.404 |
|
| 2007 |
Herzog RW. Interferon limits lentiviral vectors in the liver Blood. 109: 2670-2671. DOI: 10.1182/Blood-2007-01-067207 |
0.421 |
|
| 2006 |
Warrington KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Human Genetics. 119: 571-603. PMID 16612615 DOI: 10.1007/S00439-006-0165-6 |
0.417 |
|
| 2006 |
Herzog RW, Cao O, Hagstrom JN, Wang L. Gene therapy for treatment of inherited haematological disorders. Expert Opinion On Biological Therapy. 6: 509-22. PMID 16610980 DOI: 10.1517/14712598.6.5.509 |
0.502 |
|
| 2006 |
Cao O, Armstrong E, Schlachterman A, Wang L, Okita DK, Conti-Fine B, High KA, Herzog RW. Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. Blood. 108: 480-6. PMID 16543469 DOI: 10.1182/Blood-2005-11-4668 |
0.684 |
|
| 2006 |
Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, Herzog RW. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 4592-7. PMID 16537361 DOI: 10.1073/Pnas.0508685103 |
0.572 |
|
| 2006 |
Hoffman BE, Herzog RW. Initial Identification of a Mouse Human Factor IX-Specific CD8+ T-Cell Epitope. Blood. 108: 5490-5490. DOI: 10.1182/Blood.V108.11.5490.5490 |
0.474 |
|
| 2006 |
Cao O, Wang L, Nayak S, Herzog RW. Regulatory CD4+CD25+ T Cells Are Required for Tolerance Induction to Factor IX by In Vivo Gene Transfer. Blood. 108: 452-452. DOI: 10.1182/Blood.V108.11.452.452 |
0.766 |
|
| 2006 |
Niemeyer GP, Herzog RW, Mount JD, Arruda V, Tillson M, Hathcock J, High KA, Lothrop CD. Six-Year Follow-Up of Inhibitor Prone Hemophilia B Dogs Treated with Muscle and Liver-Directed AAV2 Mediated Factor IX Gene Therapy. Blood. 108: 3282-3282. DOI: 10.1182/Blood.V108.11.3282.3282 |
0.606 |
|
| 2006 |
Wang L, Dobrzynski E, Fitzgerald J, Cao O, Herzog RW. 76. In Vivo Suppression of Cytotoxic T Cell Responses by CD4+ Regulatory T Cells Activated by Hepatic Gene Transfer Molecular Therapy. 13: S32. DOI: 10.1016/J.Ymthe.2006.08.093 |
0.558 |
|
| 2005 |
Dobrzynski E, Herzog RW. Tolerance induction by viral in vivo gene transfer. Clinical Medicine & Research. 3: 234-40. PMID 16303889 DOI: 10.3121/Cmr.3.4.234 |
0.585 |
|
| 2005 |
Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Current Gene Therapy. 5: 349-60. PMID 15975012 DOI: 10.2174/1566523054065048 |
0.443 |
|
| 2005 |
Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Therapy. 12: 1453-1464. PMID 15889137 DOI: 10.1038/Sj.Gt.3302539 |
0.572 |
|
| 2005 |
Herzog RW. Recent advances in hepatic gene transfer: more efficacy and less immunogenicity. Current Opinion in Drug Discovery & Development. 8: 199-206. PMID 15782544 |
0.37 |
|
| 2005 |
Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood. 105: 4226-34. PMID 15713796 DOI: 10.1182/Blood-2004-03-0848 |
0.495 |
|
| 2005 |
Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood. 105: 2316-23. PMID 15550487 DOI: 10.1182/Blood-2004-08-2990 |
0.421 |
|
| 2005 |
Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW, Couto LB, High KA. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood. 105: 3458-64. PMID 15479726 DOI: 10.1182/Blood-2004-07-2908 |
0.593 |
|
| 2005 |
Cao O, Armstrong E, Conti-Fine BM, High KA, Herzog RW. Suppression of Inhibitor Formation to F.IX in Gene Transfer through Immune Deviation Induced by Mucosal Peptide Administration. Blood. 106: 211-211. DOI: 10.1182/Blood.V106.11.211.211 |
0.662 |
|
| 2005 |
Wang L, Lord EM, Herzog R. 687. Tracking Transgene Product-Specific T Cells In Vivo Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.227 |
0.486 |
|
| 2005 |
Cao O, Dobrzynski E, Mingle BL, Wang L, Herzog RW. 419. Generation of Transgene Product-Specific Regulatory CD4+CD25+ T Cells by Hepatic AAV Gene Transfer Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.422 |
0.469 |
|
| 2005 |
Cooper M, Hauck B, Watkins J, Erne M, Mingozzi F, Herzog R, Wright F. 132. An Optimized CsCl Gradient -Based Method to Generate High Concentration AAV Vector Stocks of High Purity and In Vivo Potency Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.137 |
0.333 |
|
| 2004 |
Liu YL, Mingozzi F, Rodriguéz-Colôn SM, Joseph S, Dobrzynski E, Suzuki T, High KA, Herzog RW. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. Human Gene Therapy. 15: 783-92. PMID 15319035 DOI: 10.1089/1043034041648453 |
0.629 |
|
| 2004 |
Sabatino DE, Armstrong E, Edmonson S, Liu YL, Pleimes M, Schuettrumpf J, Fitzgerald J, Herzog RW, Arruda VR, High KA. Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene. Blood. 104: 2767-74. PMID 15217833 DOI: 10.1182/Blood-2004-03-1028 |
0.612 |
|
| 2004 |
Herzog RW, Dobrzynski E. Immune implications of gene therapy for hemophilia. Seminars in Thrombosis and Hemostasis. 30: 215-26. PMID 15118933 DOI: 10.1055/S-2004-825635 |
0.57 |
|
| 2004 |
Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, Wang L, Herzog RW. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood. 104: 969-77. PMID 15105293 DOI: 10.1182/Blood-2004-03-0847 |
0.547 |
|
| 2004 |
Herzog RW. AAV-mediated gene transfer to skeletal muscle. Methods in Molecular Biology (Clifton, N.J.). 246: 179-94. PMID 14970592 DOI: 10.1385/1-59259-650-9:179 |
0.478 |
|
| 2004 |
Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, Lotfi Y, Mingozzi F, Xiao W, Couto LB, High KA. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 103: 85-92. PMID 12969984 DOI: 10.1182/Blood-2003-05-1446 |
0.652 |
|
| 2004 |
Cao O, Armstrong E, Conti-Fine BM, High KA, Herzog RW. Prevention of Gene Transfer-Induced Inhibitor Formation by Nasal Administration of Human F.IX T Cell Epitope in a Murine Model of Hemophilia B. Blood. 104: 414-414. DOI: 10.1182/Blood.V104.11.414.414 |
0.682 |
|
| 2004 |
High K, Tigges M, Manno C, Sabatino D, Arruda V, Herzog R, Rustagi P, Rasko J, Sommer J, Jaworski K, Ragni M, Glader B, Lessard R, Luk A, Couto L, et al. Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B. Blood. 104: 413-413. DOI: 10.1182/Blood.V104.11.413.413 |
0.605 |
|
| 2004 |
Dobrzynski E, Mingozzi F, Wang L, Mingle B, Cao O, Herzog RW. Hepatic Tolerance Induction Prevents Inflammatory Responses To Factor IX Expressing Cells at Supplementary Sites of Gene Transfer. Blood. 104: 3185-3185. DOI: 10.1182/Blood.V104.11.3185.3185 |
0.538 |
|
| 2004 |
Herzog RW. Lentiviral vector for hemophilia gene therapy Blood. 103: 3609-3610. DOI: 10.1182/Blood-2004-03-0820 |
0.457 |
|
| 2004 |
High K, Manno C, Sabatino D, Hutchison S, Dake M, Razavi M, Kaye R, Aruda V, Herzog R, Rustagi P, Rasko J, Hoots K, Blatt P, Sommer J, Ragni M, et al. 1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.940 |
0.614 |
|
| 2004 |
Wang L, Dobrzynski E, Cao O, Herzog R. 185. Systemic Protein Delivery by Muscle-Directed Gene Transfer Is Limited by a Local Immune Response Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.147 |
0.542 |
|
| 2004 |
Arruda V, Scallan C, Jiang H, Couto L, Herzog RW, Nichols T, Pierce G, High KA. 103. Comparison of the Efficacy on Gene Transfer by AAV Vectors Delivered by Distinct Routes of Administration to the Liver of Hemophilia B Dogs Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.040 |
0.585 |
|
| 2004 |
Dobrzynski E, Wang L, Cao O, Mingozzi F, Herzog RW. 33. Induction of Antigen-Specific T Cell Anergy and Deletion by Hepatic AAV Gene Transfer Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.056 |
0.543 |
|
| 2003 |
Herzog RW, Arruda VR. Update on gene therapy for hereditary hematological disorders. Expert Review of Cardiovascular Therapy. 1: 215-32. PMID 15030282 DOI: 10.1586/14779072.1.2.215 |
0.523 |
|
| 2003 |
Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, Arruda VR, High KA, Herzog RW. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. The Journal of Clinical Investigation. 111: 1347-56. PMID 12727926 DOI: 10.1172/Jci16887 |
0.715 |
|
| 2003 |
Liu Y-, Wagner K, Robinson N, Sabatino D, Margaritis P, Xiao W, Herzog RW. Optimized production of high-titer recombinant adeno-associated virus in roller bottles. Biotechniques. 34: 184-189. PMID 12545558 DOI: 10.2144/03341Dd07 |
0.375 |
|
| 2003 |
Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 101: 2963-72. PMID 12515715 DOI: 10.1182/Blood-2002-10-3296 |
0.643 |
|
| 2002 |
Mingozzi F, Schüttrumpf J, Arruda VR, Liu Y, Liu YL, High KA, Xiao W, Herzog RW. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. Journal of Virology. 76: 10497-502. PMID 12239326 DOI: 10.1128/Jvi.76.20.10497-10502.2002 |
0.612 |
|
| 2002 |
Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Human Gene Therapy. 13: 1281-91. PMID 12162811 DOI: 10.1089/104303402760128513 |
0.611 |
|
| 2002 |
Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, Bellinger D, Nichols TC, Arruda VR, Lothrop CD, High KA. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 99: 2670-6. PMID 11929752 DOI: 10.1182/Blood.V99.8.2670 |
0.625 |
|
| 2001 |
Herzog RW, Hagstrom JN. Gene therapy for hereditary hematological disorders. American Journal of Pharmacogenomics. 1: 137-144. PMID 12174674 DOI: 10.2165/00129785-200101020-00006 |
0.488 |
|
| 2001 |
Arruda VR, Fields PA, Milner R, Wainwright L, De Miguel MP, Donovan PJ, Herzog RW, Nichols TC, Biegel JA, Razavi M, Dake M, Huff D, Flake AW, Couto L, Kay MA, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 586-92. PMID 11735343 DOI: 10.1006/Mthe.2001.0491 |
0.548 |
|
| 2001 |
Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, Herzog RW, High KA. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9 Molecular Therapy. 4: 201-210. PMID 11545610 DOI: 10.1006/Mthe.2001.0441 |
0.661 |
|
| 2001 |
Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation Molecular Therapy. 4: 192-200. PMID 11545609 DOI: 10.1006/Mthe.2001.0442 |
0.635 |
|
| 2001 |
Fields PA, Armstrong E, Hagstrom JN, Arruda VR, Murphy ML, Farrell JP, High KA, Herzog RW. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Therapy. 8: 354-61. PMID 11313811 DOI: 10.1038/Sj.Gt.3301409 |
0.611 |
|
| 2001 |
Arruda VR, Hagstrom JN, Deitch J, Heiman-Patterson T, Camire RM, Chu K, Fields PA, Herzog RW, Couto LB, Larson PJ, High KA. Posttranslational modifications of recombinant myotube-synthesized human factor IX Blood. 97: 130-138. PMID 11133752 DOI: 10.1182/Blood.V97.1.130 |
0.564 |
|
| 2000 |
Herzog RW, Arruda VR, Fisher TH, Read MS, Nichols TC, High KA. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony Thrombosis and Haemostasis. 84: 352-354. PMID 10959714 DOI: 10.1055/S-0037-1614021 |
0.525 |
|
| 2000 |
Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HCJ, Herzog RW, High KA. Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX Molecular Therapy. 1: 225-235. PMID 10933938 DOI: 10.1006/Mthe.2000.0032 |
0.677 |
|
| 2000 |
Hagstrom JN, Couto LB, Scallan C, Burton M, McCleland ML, Fields PA, Arruda VR, Herzog RW, High KA. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter Blood. 95: 2536-2542. PMID 10753832 DOI: 10.1182/Blood.V95.8.2536.008K26_2536_2542 |
0.607 |
|
| 2000 |
Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genetics. 24: 257-61. PMID 10700178 DOI: 10.1038/73464 |
0.625 |
|
| 1999 |
Herzog RW, High KA. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy Thrombosis and Haemostasis. 82: 540-546. PMID 10605748 DOI: 10.1055/S-0037-1615877 |
0.658 |
|
| 1999 |
Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine. 5: 56-63. PMID 9883840 DOI: 10.1038/4743 |
0.635 |
|
| 1998 |
Herzog RW, High KA. Problems and prospects in gene therapy for hemophilia Current Opinion in Hematology. 5: 321-326. PMID 9776210 DOI: 10.1097/00062752-199809000-00003 |
0.63 |
|
| 1998 |
Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, Yang EY, Tai SJ, Iwaki Y, Kurtzman GJ, Fisher KJ, Colosi P, Couto LB, High KA. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 91: 4600-7. PMID 9616156 DOI: 10.1182/Blood.V91.12.4600.412K22_4600_4607 |
0.591 |
|
| 1998 |
Redkar RJ, Herzog RW, Singh NK. Transcriptional activation of the Aspergillus nidulans gpdA promoter by osmotic signals. Applied and Environmental Microbiology. 64: 2229-31. PMID 9603839 DOI: 10.1128/Aem.64.6.2229-2231.1998 |
0.445 |
|
| 1997 |
Herzog RW, Singh NK, Urry DW, Daniell H. Expression of a synthetic protein-based polymer (elastomer) gene in Aspergillus nidulans. Applied Microbiology and Biotechnology. 47: 368-72. PMID 9163950 DOI: 10.1007/S002530050942 |
0.491 |
|
| 1997 |
Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proceedings of the National Academy of Sciences of the United States of America. 94: 5804-9. PMID 9159155 DOI: 10.1073/Pnas.94.11.5804 |
0.618 |
|
| 1995 |
Herzog RW, Singh NK, Schmidt C, Lemke PA. Presence of a P1 bacteriophage sequence in transforming plasmids of Pleurotus ostreatus. Current Genetics. 27: 460-5. PMID 7586033 DOI: 10.1007/Bf00311216 |
0.696 |
|
| Show low-probability matches. |